A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients

Khan, Tanveer A.; Schnickel, Gabriel T.; Ross, David J.; Bastani, S.; Laks, Hillel; Esmailian, F.; Marelli, Daniel; Beygui, Ramin E.; Shemin, Richard J.; Watson, Larry; Vartapetian, Irina; Ardehali, A.

doi:10.1016/j.jtcvs.2009.04.063

Cited by 140 publications

(105 citation statements)

References 26 publications

Supporting

Mentioning

103

Contrasting

Order By: Relevance

“…501 The short-term effects of inhaled PGI 2 , milrinone, and nitroglycerin may be as effective as iNO at lowering PVRI and improving intrapulmonary shunt fraction with minimal decreases in systemic hemodynamics. 294,[501][502][503][504] In a placebo-controlled trial, intravenous sildenafil reduced PAP and shortened the time to extubation and intensive care unit stay without adverse events in children after cardiac surgery. 475 A randomized, prospective trial in children compared intravenous sildenafil with iNO therapy and reported augmentation of pulmonary vasodilation with combined treatment.…”

Section: Pah-specific Drug Therapy Of Acute Postoperative Phmentioning

confidence: 99%

Pediatric Pulmonary Hypertension

Abman¹,

Hansmann²,

Archer³

et al. 2015

Circulation

948

405

View full text Add to dashboard Cite

Abstract-Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic diseases in neonates, infants, and older children and contributes to significant morbidity and mortality. However, current approaches to caring for pediatric patients with pulmonary hypertension have been limited by the lack of consensus guidelines from experts in the field. In a joint effort from the American Heart Association and American Thoracic Society, a panel of experienced clinicians and clinician-scientists was assembled to review the current literature and to make recommendations on the diagnosis, evaluation, and treatment of pediatric pulmonary hypertension. This publication presents the results of extensive literature reviews, discussions, and formal scoring of recommendations for the care of children with pulmonary hypertension. Key Words: AHA Scientific Statements ◼ bronchopulmonary dysplasia ◼ congenital diaphragmatic hernia ◼ congenital heart disease ◼ genetics ◼ persistent pulmonary hypertension of the newborn ◼ sickle cell disease © 2015 by the American Heart Association, Inc., and the American Thoracic Society.Circulation is available at http://circ.ahajournals.org DOI: 10.1161/CIR.0000000000000329 †Deceased. The American Heart Association and the American Thoracic Society make every effort to avoid any actual or potential conflicts of interest that may arise as a result of an outside relationship or a personal, professional, or business interest of a member of the writing panel. Specifically, all members of the writing group are required to complete and submit a Disclosure Questionnaire showing all such relationships that might be perceived as real or potential conflicts of interest.This document was approved by the American Heart Association Science Advisory and Coordinating Committee on May 12, 2015, the American Heart Association Executive Committee on July 22, 2015, and the American Thoracic Society on July 24, 2015.The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/doi:10.1161/CIR.0000000000000329/-/DC1. The American Heart Association requests that this document be cited as follows: Abman SH, Hansmann G, Archer SL, Ivy DD, Adatia I, Chung WK, Hanna BD, Rosenzweig EB, Raj JU, Cornfield D, Stenmark KR, Steinhorn R, Thébaud B, Fineman JR, Kuehne T, Feinstein JA, Friedberg MK, Earing M, Barst RJ, Keller RL, Kinsella JP, Mullen M, Deterding R, Kulik T, Mallory G, Humpl T, Wessel DL; on behalf of the American Heart Association Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Clinical Cardiology, Council on Cardiovascular Disease in the Young, Council on Cardiovascular Radiology and Intervention, Council on Cardiovascular Surgery and Anesthesia, and the American Thoracic Society. Pediatric pulmonary hypertension: guidelines from the American Heart Association and American Thoracic Society. Circulation. 2015;132:2037-2099 Copies: This document is available on the World Wide Web site of the American Heart Associat...

show abstract

Section: Pah-specific Drug Therapy Of Acute Postoperative Phmentioning

confidence: 99%

Pediatric Pulmonary Hypertension

Abman¹,

Hansmann²,

Archer³

et al. 2015

Circulation

948

405

View full text Add to dashboard Cite

show abstract

“…The inhalation of these agents appears to be superior to a systemic administration of prostaglandins or other pulmonary vasodilators as the pulmonary artery bed is widened more selectively and systemic vasodilation and consequent systemic hypotension can be prevented. 11 The newly transplanted heart needs appropriate filling pressures, being completely preload dependent. However high central venous pressures and right ventricular overdistension should be avoided.…”

Section: The Calculation Of the Pulmonary Artery Vascular Resistance mentioning

confidence: 99%

Cardiac Transplantation: An Anesthetic Challenge

Premalatha¹,

Jayaraman²

2017

jemds

View full text Add to dashboard Cite

Heart transplantation has emerged as the definitive therapy for patients with end-stage cardiomyopathy. The two most common forms of cardiac disease that lead to transplantation are ischemic cardiomyopathy and dilated cardiomyopathy, which together comprise approximately 90% of cases. The other less common forms of heart disease include viral cardiomyopathy, infiltrative cardiomyopathy, postpartum cardiomyopathy, valvular heart disease and congenital heart disease.

show abstract

“…Inhaled epoprostenol is generally the preferred agent in the ICU setting given its short half-life and ease of use [28]. Inhaled epoprostenol improves pulmonary artery pressures and cardiac index comparably to inhaled nitric oxide in patients with right heart failure after heart and lung transplantation and may be more effective at reducing afterload in patients with pulmonary hypertension [44][45][46]. Inhaled prostacyclins are generally more cost-effective than inhaled nitric oxide and have become the preferred inhaled pulmonary vasodilator in many centers.…”

Section: Afterload Reductionmentioning

confidence: 99%

Management of Pulmonary Hypertension and Right Heart Failure in the Intensive Care Unit

Grinstein

Gomberg‐Maitland

2015

Curr Hypertens Rep

View full text Add to dashboard Cite

Management of acute right ventricular failure, both with and without coexisting pulmonary hypertension, is a common challenge encountered in the intensive care setting. Both right ventricular dysfunction and pulmonary hypertension portend a poor prognosis, regardless of the underlying cause and are associated with significant morbidity and mortality. The right ventricle is embryologically distinct from the left ventricle and has unique morphologic and functional properties. Management of right ventricular failure and pulmonary hypertension in the intensive care setting requires tailored hemodynamic management, pharmacotherapy, and often mechanical circulatory support. Unfortunately, our understanding of the management of right ventricular failure lags behind that of the left ventricle. In this review, we will explore the underlying pathophysiology of the failing right ventricle and pulmonary vasculature in patients with and without pulmonary hypertension and discuss management strategies based on evidence-based studies as well as our current understanding of the underlying physiology.

show abstract

A prospective, randomized, crossover pilot study of inhaled nitric oxide versus inhaled prostacyclin in heart transplant and lung transplant recipients

Cited by 140 publications

References 26 publications

Pediatric Pulmonary Hypertension

Pediatric Pulmonary Hypertension

Cardiac Transplantation: An Anesthetic Challenge

Management of Pulmonary Hypertension and Right Heart Failure in the Intensive Care Unit

Contact Info

Product

Resources

About